Clinical Trial Update: Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pembrolizumab in advanced recurrent ovarian cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2020-09-22